Down-regulation of CIT can inhibit the growth of human bladder cancer cells.

@article{Liu2020DownregulationOC,
  title={Down-regulation of CIT can inhibit the growth of human bladder cancer cells.},
  author={Zan Liu and Haiyan Yan and Yang Yang and Liang Wei and Shunyao Xia and Youcheng Xiu},
  journal={Biomedicine \& pharmacotherapy = Biomedecine \& pharmacotherapie},
  year={2020},
  volume={124},
  pages={
          109830
        }
}
  • Zan Liu, Haiyan Yan, Youcheng Xiu
  • Published 20 January 2020
  • Biology, Medicine
  • Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
1 Citations
Oncogenic FGFR Fusions Produce Centrosome and Cilia Defects by Ectopic Signaling
TLDR
It is speculated that the functions of centrosome proteins are often lost with the gene fusion, leading to haploinsufficiency that induces cilia loss and deregulated cell division, and that this complements the ectopic FGFR activity and drives the FGFR fusion cancers.

References

SHOWING 1-10 OF 25 REFERENCES
Up-regulation of CIT promotes the growth of colon cancer cells
TLDR
It is demonstrated that citron rho-interacting, serine/threonine kinase 21 (CIT) promotes the growth of human colon cancer cells, and microarray and bioinformatics analyses indicated that CIT regulates the p53 signaling pathway, which may account for the effects of CIT on Colon cancer cells.
Cell Cycle Regulators in Bladder Cancer: Relationship to Schistosomiasis
Dysregulation of cell cycle control may lead to genomic instability, neoplastic transformation and tumor progression. In terms of the particular roles in regulation of the cell‐cycle, p21(WAF1)
Citron Rho-interacting kinase silencing causes cytokinesis failure and reduces tumor growth in multiple myeloma.
TLDR
This study identified, by protein microarray and immunohistochemistry, that CIT is 1 of the upregulated proteins in the plasma cells of MM patients compared with healthy controls and provides the rationale for CIT being a potential therapeutic target in MM in future trials.
Prognostic value of cell-cycle regulation biomarkers in bladder cancer.
TLDR
This review will discuss alterations in molecules within pathways controlling cell-cycle regulation in the context of bladder cancer, and their impact on patient outcome when examined individually and in combination.
RNA interference targeting CITRON can significantly inhibit the proliferation of hepatocellular carcinoma cells
TLDR
The data suggest that CITRON may be a potential target for therapeutic intervention in HCC and indicate that adenovirus-mediated RNA interference can suppress tumourigenicity in vivo of HCC cells.
Minichromosome Maintenance Protein 7 is a potential therapeutic target in human cancer and a novel prognostic marker of non-small cell lung cancer
TLDR
Since MCM7 expression was generally low in a number of normal tissues it has the characteristics of an ideal candidate for molecular targeted cancer therapy in various tumors and also as a good prognostic biomarker for NSCLC patients.
Flavopiridol, an inhibitor of cyclin-dependent kinases, induces growth inhibition and apoptosis in bladder cancer cells in vitro and in vivo.
TLDR
It is indicated that flavopiridol could be a useful therapeutic agent for bladder cancer, inhibiting tumor growth, malignant progression and inducing apoptosis.
The impact of cyclin D1 overexpression on the prognosis of bladder cancer: a meta-analysis
TLDR
Increased cyclin D1 expression level detected by immunohistochemistry is associated with good progression-free survival for bladder cancer and further well-designed prospective studies are warranted to confirm the findings.
The history and future of targeting cyclin-dependent kinases in cancer therapy
TLDR
How CDK inhibitors with high selectivity (particularly for both CDK4 and CDK6), in combination with patient stratification, have resulted in more substantial clinical activity is discussed.
...
...